Evidence map›Paper›PMID 41725422›Full record

ArticleDiabetes, obesity & metabolism2026

Flexible dose of semaglutide reduces early discontinuation while maintaining comparable outcomes in obese patients: FLEX-SEMA 2.4 mg, an Italian real-world study.

Simone Pampanelli, Stefano Terzoni, Paola Pantanetti, Chiara Di Loreto, Alessio Mazzieri, Giovanni Cangelosi, Sara Alberti, Cristina Badiali, Ilenia Grandone, Sara Migliarelli and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Simone PampanelliSS Clinical Nutrition and Dietetics Hospital Santa Maria Novella, Perugia, Italy.ORCID https://orcid.org/0000-0003-0255-4210
Stefano TerzoniDepartment of Biomedical Sciences for Health, University of Study of Milano, Milan, Italy.
Paola PantanettiUOSD Diabetology AST Fermo, Fermo, Italy.
Chiara Di LoretoUSL Umbria 1, Perugia, Italy.
Alessio MazzieriUSL Umbria 1, Perugia, Italy.
Giovanni CangelosiUOSD Diabetology AST Fermo, Fermo, Italy.
Sara AlbertiUOSD Diabetology AST Fermo, Fermo, Italy.
Cristina BadialiUOSD Hospital Clinical Nutrition San Donato, Arezzo, Italy.
Ilenia GrandoneSC University Department of Andrology and Endocrinology Metabolic Diseases, Terni, Italy.
Sara MigliarelliUnveristy of Perugia, Perugia, Italy.
Maria Grazia CastagnaUOC Endocrinology, Siena Hospital, Siena, Italy.
Mariaclaudia Cerrai CeroniUOC Endocrinology, Siena Hospital, Siena, Italy.
Nicoletta BenenatiUOC Endocrinology, Siena Hospital, Siena, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo evaluate real-world clinical use of semaglutide in obese patients, focusing on titration, tolerability and short-term efficacy. MATERIALS AND

methodsThis retrospective study included obese patients treated with the weekly injectable semaglutide. Data on body weight, waist circumference, lipid profile, doses, reasons for maintenance, adverse events, and discontinuations were collected at 3 and 6 months.

resultsA total of 111 patients were included (80% women; mean age 51.12; median body mass index (BMI) 35.56 kg/m

conclusionThis real-world analysis provides valuable insights into the use of semaglutide in routine clinical practice, confirming a favourable efficacy profile with flexible dosing patterns.

Indexed as

Anti-Obesity AgentsDiabetes Mellitus, Type 2Glucagon-Like PeptidesObesityAdultBody Mass IndexDrug Administration ScheduleFemaleHumansItalyMaleMiddle AgedRetrospective StudiesSemaglutideTreatment OutcomeWaist CircumferenceAnti-Obesity AgentsGlucagon-Like PeptidesSemaglutideobesity carereal‐world evidencesemaglutideweight management

Identifiers

PMID41725422
PMCPMC13071210

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.